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Abstract
Background: Influenza virus (IFV) infection is associated with increased morbidity and mortality in people with
underlying lung disease. Treatment options for IFV are currently limited and antiviral resistance is a growing
concern. DAS181, an inhaled antiviral with a unique mechanism of action, has shown promise in early clinical trials
involving generally healthy human subjects. This study was undertaken to assess the safety and tolerability of
DAS181 in individuals with underlying reactive airway disease.
Methods: This was a randomized, double-blind, placebo-controlled, crossover phase 1 study of DAS181-F02. Dry
particle inhaler administration of 10 mg was done on 3 consecutive days in ten adult volunteers with well-
controlled asthma. The primary outcome was the frequency of adverse events (AEs), grade 1 or higher that
occurred during each study period.
Results: There were 280 AEs among ten evaluable subjects (56.8 % active; 43.2 % placebo); 90.7 % were grade 1.
No grade 3 or higher AEs occurred. A statistically significant association between exposure to DAS181 and
experiencing any AE, a grade 1 AE, or a grade 2 AE was not detected. Overall, the majority of AEs were classified as
possibly related (35.7 %), unlikely related (38.9 %), or unrelated (15.4 %) to study drug administration. However,
there was a statistically significant association between exposure to DAS181 and experiencing a definitely or
probably related AE. Respiratory effects, including dyspnea, dry cough, and chest discomfort related to respirations,
accounted for all of the definitely related AEs and one of the most common probably related AEs.
Conclusions: DAS181 was safe in this small study of otherwise healthy subjects with well-controlled asthma.
However, the generalizability of these results is limited by the small sample size and generally mild nature of the
subjects’ asthma at baseline. The increased association of respiratory events classified as probably or definitely
related to DAS181 administration suggests caution may need to be employed when administering DAS181 to
individuals with less stable reactive airway disease. Further investigation in a controlled setting of the safety and
efficacy of DAS181 in a larger population of asthmatic subjects with varying disease activity is warranted.
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Background
In 2009, a novel subtype of influenza A virus (IFV A) cap-
able of infecting humans emerged. This virus, designated
A(H1N1)pdm09, was responsible for a worldwide pan-
demic that ultimately caused an estimated 61 million infec-
tions and at least 12,700 deaths [1]. Children and young
adults were affected in the majority of cases, typically with
acute, self-limited illness. Severe infections occurred with
higher frequency among specific populations, including
individuals who had an underlying medical condition such
as a chronic lung disease [2]. Between 24 and 50 % of indi-
viduals hospitalized with A(H1N1)pdm09 infection had a
history of asthma, and 36 % of adults had a history of
chronic obstructive pulmonary disease (COPD) [2].
The 2009 pandemic heightened awareness of the
current limitations for treating influenza and brought into
stark relief the need for alternative approaches to treating
influenza virus (IFV). Similar to the prior seasonal H1N1
subtype virus in circulation, the A(H1N1)pdm09 virus was
almost uniformly resistant to the adamantane antivirals.
Fortunately, the majority of tested strains retained in vitro
susceptibility to the neuraminidase inhibitors oseltamivir
and zanamivir, although more than 300 cases of oseltami-
vir resistant influenza cases were ultimately reported [3].
Treatment options are very limited in suspected cases of
oseltamivir resistance particularly in people with
underlying lung disease. Until the FDA approved per-
amivir for influenza treatment in December 2014, the
only other licensed antiviral available for treating ada-
mantane and oseltamivir-resistant virus was inhaled
zanamivir, an agent that is relatively contraindicated
in individuals with pre-existing reactive airway disease
due to the potential for bronchospasm [4].
DAS181, a recombinant fusion protein composed of a
sialidase catalytic domain and a cationic amphiregulin
(AR) glycosaminoglycan-binding sequence, offers a novel
approach to the treatment of IFV [5]. DAS181 works by
targeting the host cell receptors to prevent IFV attach-
ment and spread. The host cell receptors for IFV A and
IFV B viruses are cell surface sialic acids. The sialidase
catalytic domain in DAS181 selectively cleaves sialic
acids from the host cells, thereby rendering them refrac-
tory to binding by virus particles that require sialic acid
as receptors. By binding to the negatively charged gly-
cosaminoglycans on the surface of airway epithelial cells,
the cationic C-terminal AR tag anchors DAS181 on the
respiratory epithelium, thereby improving treatment
potency and retention of the drug on the airway surface
[5]. The unique mechanism of action potentially affords
DAS181 a broad spectrum of antiviral activity against
any virus that uses host cell surface sialic acids as recep-
tors, including all strains of IFV A and IFV B.
In previous studies enrolling healthy subjects, DAS181
has had an acceptable safety profile with no reported
serious adverse events, no significant alterations in lung
function, and no anaphylaxis or hypersensitivity reac-
tions in phase I studies. DAS181 also showed promising
antiviral activity during a phase II study in IFV positive
but otherwise healthy adult subjects [6]. DAS181 was
well tolerated in this phase II trial, with only 2 (2 %) ser-
ious adverse events (AEs) in both the DAS181 treated
and placebo group. There were more mild to moderate
treatment-related, treatment-emergent adverse events in
the DAS181 treatment group than the placebo, with the
most common being a transient elevation in serum alka-
line phosphatase. There was one death, due to pneumo-
nia, in the DAS181 group, however this was assessed as
not related to the study drug and occurred in a patient
with previously unknown HIV infection. Inasmuch as
the clinical trials to date have focused on subjects with-
out known chronic health conditions, there is a strong
need to investigate this agent in subjects with underlying
lung disease as well. These individuals are at increased
risk of developing influenza-related complications yet
have fewer available treatment options given the relative
contraindication to use of zanamivir in patients with
underlying reactive airway disease. DAS181, like zanami-
vir, is administered as a dry particle inhalant. However,
in phase I and phase II studies to date, there has been
no evidence of bronchial hyperreactivity among healthy
subjects receiving DAS181.
This research study was undertaken to evaluate the
safety and tolerability of DAS181 (Formulation DAS181-
02) in individuals with well-controlled asthma.
Methods
Study design
This was a randomized, double-blind, crossover phase 1
study to evaluate the safety and tolerability of three se-
quential doses of DAS181 10 mg in adult subjects with
well-controlled asthma (Fig. 1).
Study population
Adult subjects with documented asthma were recruited
from the local community. Asthmatic volunteers who
had been on stable medication regimens for at least
3 months, were not taking oral corticosteroids or theo-
phylline, and did not have any other significant medical
problems were eligible to undergo screening. Following
written informed consent, subjects who met entry cri-
teria (Additional file 1: Tables S1A and S1B) were
enrolled in the study. The planned study enrollment
size of 12 subjects with asthma (10 evaluable plus
20 % drop-out) was chosen to obtain a preliminary
assessment of safety and tolerability, while minimizing
potential risks to human subjects. The study was
stopped once ten evaluable patients completed both
arms of the study.
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Study agents
The DAS181-F02 formulation tested in this trial was a
dry powder composed of microparticles designed to de-
posit in the upper airways. The placebo was a similarly
appearing powder comprised of lactose monohydrate.
DAS181 dry powder or placebo was packaged into clear
capsules and delivered using a dry powder inhaler
(Cyclohaler®). All study subjects received training in ap-
propriate use of the Cyclohaler® prior to dosing.
Study interventions
Eligible subjects enrolled in the study were randomized to
initially receive either 10 mg of DAS181-F02 or matched
placebo via dry particle inhalation on 3 consecutive days.
Each subject was followed for an additional 18 days then
crossed over to the other treatment group (Fig. 1). The
first crossover visit could occur on the same day as the
initial period final visit or up to 6 weeks later. Data
were collected at specified time points (Additional file 1:
Table S1C: Schedule of Events/Procedures).
Subjects were blinded to their allocation and were dosed
with the study drug or placebo in a clinical research ward
at the National Institutes of Health (NIH) Clinical Center.
The subjects were eligible to receive the study drug or
placebo on either an outpatient or inpatient basis. All
subjects were monitored for at least 1 h following
drug administration. If a study subject experienced an
acute change in respiratory status, i.e., >10 % drop in the
forced expiratory volume in 1 s (FEV1) or a drop in oxy-
hemoglobin saturation to <90 %, monitoring was




The primary objective of this study was to evaluate
whether DAS181-F02 was safe in individuals with well-
controlled asthma. The primary outcome was the fre-
quency of adverse events, grade 1 or higher that occurred
during each study period (active drug vs. placebo).
Secondary
Additional data was collected to aid in the development
of future efficacy studies. Data were collected on stand-
ard measures of lung function, airway reactivity, acute
exacerbations of asthma, the need for rescue medica-
tions, and/or changes in perceived health related quality
of life. The specific exploratory outcomes assessed are
contained in Additional file 1: Table S1D.
Study evaluations
Safety and tolerability assessments conducted through-
out the study period included assessment of adverse
events based on medical history, physical exam findings,
vital sign measurements, clinical laboratory test results,
chest radiograph, spirometric lung function test, 6 min
walk test, and electrocardiography. Sputum evaluation
was also performed.
With regard to lung function, acute tolerability of
DAS181 was assessed by changes in FEV1 and oxyhemo-
globin saturation before and after each dose. Chronic ef-
fects on lung function were assessed by change in FEV1%
over time, comparing pre-dose measures at baseline
(Day0) to measures on the day following sequential dosing
(Day 3). Change in exertional capability was evaluated
Fig. 1 Schematic of study design. Subjects who met eligibility criteria during screening were randomized to receive three consecutive daily doses
of either DAS 181 or placebo starting on day 0, the first day of the initial period. Subjects were evaluated at specified time-points for an additional
18 days, then crossed-over to the other treatment group within 6 weeks of completing the initial period. Abbreviations: I = initial; CO = crossover
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using a standard 6-minute walk assessment at baseline
and day 3 [7]. Asthma exacerbation was a clinical diagno-
sis, defined according to national guidelines [8] as some
combination of worsening shortness of breath, cough,
wheezing, and/or chest tightness.
Methacholine challenge testing to assess airway reactiv-
ity was performed according to a standardized protocol
[9]. Subjects inhaled a nebulized mist prepared from a
series of increasing concentrations of methacholine. FEV1
was computed after each concentration was administered,
and the concentration of methacholine required to pro-
duce a decrease of 20 % in FEV1 was recorded as the pro-
vocative concentration producing a 20 % decline (PC20).
Change in airway reactivity was measured by the relative
change in PC20 from screening to Day 3.
Sputum was induced using a nebulized 3 % sodium
chloride solution according to standard procedure. The
induced sputum was processed for semi-quantitative
Gram’s stain and bacterial culture. Quantitative assess-
ment of the immunologic cells present in the induced
sputum was planned, however was ultimately not per-
formed due to inadequate sample collection.
Blood samples were collected at specified time points
for safety evaluation. In the case of abnormal activated
partial thromboplastin time (aPTT) values, further investi-
gation with a Kaolin clotting time (KCT) was performed
to evaluate whether there was a true coagulation abnor-
mality or an in vitro phenomenon related to the sialidase
potentially interfering with in vitro assays via phospholipid
interactions.
Changes in perceived health related quality of life at day
10 versus baseline were assessed using three questionnaires
validated for use in asthma: the acute Short Form-36
(SF-36) Health Survey, the Asthma Control Survey (ACS),
and the Asthma Quality of Life Questionnaire (AQLQ).
The acute SF-36 is a generic self-administered health
questionnaire comprised of 36 questions that yield an 8-
scale profile of functional health and well-being with a 1-
week recall period [10]. The ACS has 7 question designed
to measure asthma control and change in asthma control;
use of a shortened version that excludes measurement of
either FEV1 or peak flow has also been validated [11]. The
AQLQ is a 32-question questionnaire developed to meas-
ure the primary functional problems in adults with asthma
and encompasses 4 domains: symptoms, activity limita-
tion, emotional function, and environmental stimuli [12].
Study oversight
This study was approved by the National Institutes of
Allergy and Infectious Diseases (NIAID) Institutional
Review Board and was conducted in compliance with
Good Clinical Practice Guidelines, the Declaration of
Helsinki, and local regulatory requirements. The study
was designed and conducted by NIAID investigators at
the NIH and was funded by the Division of Intramural
Research. The study drug, delivery device, and matched
placebo were provided by the manufacturer of DAS181,
Ansun Biopharma, Inc. The study agent and placebo
were pre-randomized by the NIH Pharmaceutical Develop-
ment Section (PDS) using a computer generated sequence.
The randomization code was maintained by the PDS in a
sealed envelope and stored in a locked cabinet with access
available only for emergencies. Block randomization was
done for the first four patients followed by review of safety
data by an independent Safety Monitoring Committee.
Stopping rules included any serious adverse event or Grade
4 adverse event deemed definitely or probably related to
the study drug, anaphylactic or other life threatening reac-
tion or acute drop in FEV1 to <50 % in response to study
drug administration, or observed hemolysis associated or
probably associated with the study drug.
Analysis
Primary endpoint
To assess safety, the percentage experiencing at least
one severe adverse event (SAE) was estimated by treat-
ment arm, along with 95 % confidence intervals (CIs).
The number and percentage of participants who experi-
enced at least one AE of any severity and 95 % CIs were
also determined. Additionally, AE rates by type of AE
were tabulated by severity and relationship to treatment.
Each adverse event was graded according to the 2009
Division of AIDS (DAIDS) Table for Grading Severity of
Adverse Events [13]. For all collected AEs, the blinded
clinician who examined and evaluated the subject deter-
mined the AE’s causality based on temporal relationship
and his/her clinical judgment. The degree of certainty
about causality was graded as definitely related, probably
related, possibly related, unlikely related, unrelated, or
as an expected event related to disease process. The
study’s principle investigator (PI) made the final de-
termination of AE grading and study drug relatedness
prior to unblinding.
AEs were recorded for all randomized subjects who re-
ceived at least one dose of study drug or placebo. How-
ever, only those subjects who completed both periods of
the study were considered evaluable for safety analysis
due to the pre-specified constraints of the crossover de-
sign. Events that occurred prior to screening and those
that occurred after screening but prior to the first
dose of initial period study drug (active or placebo)
were considered pre-existing and were thus not included
in the analysis.
Secondary endpoints
As a secondary analysis, the AE rates by period were
examined. Analyses included the estimation of 1) the
probability of an AE during the control period but no
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AE during the active drug period, and 2) the probability
of no AE during the control period but an AE during
the active drug period. The difference in AE rates by
treatment arm was assessed using a McNemar’s test with
continuity correction. With ten subjects this test had
80 % power if the true rate of patients having an AE with
control was 0 and with treatment was 0.65.
For categorical variables, the numbers and percentages
were tabulated; for continuous variables, the mean and
standard deviation (SD) were determined for normally dis-
tributed values and median and interquartile range (IQR)
were determined for variables with non-parametric distri-
bution. For continuous variables, paired t-tests and non-
parametric methods, such as the Wilcoxon signed rank
test, were used to assess differences in the patient experi-
ence on active versus placebo. Statistical analysis was con-
ducted using Excel and SAS Enterprise Guide version 4.3
(SAS Inc., Cary, NC 2006–2010).
Results
Demographics
A total of 22 subjects were screened to enroll 11 subjects
(50 % screen failure rate). Among these 11 subjects who
were randomized to receive study drug, one subject volun-
tarily withdrew from the study after completing only the
initial period due to scheduling conflicts. As he did not
complete both periods he was excluded from further ana-
lysis; after completion of the study it was determined that
he had received placebo. Table 1 contains the demographic
characteristics for the ten evaluable subjects. Each subject
served as his or her own control for this crossover study.
Primary outcome: adverse events
A total of 318 AEs occurred among the 11 enrolled sub-
jects after screening and before study conclusion. How-
ever, 29 (9.1 %) were excluded from analysis because
they did not fulfill the pre-specified criteria for inclusion
as they occurred after screening but before dosing dur-
ing the initial period and/or occurred in the subject who
did not complete both periods of the study. Nine of the
remaining AEs were documented between the last study
point of the initial period (I/21) and the initial dose of
study medication (placebo or active) on day 0 of the cross-
over period. These were characterized as “between-
period” AEs. All 9 had been classified as either unrelated
(89 %) or unlikely related (11 %) to the study drug. Ana-
lysis was performed with and without inclusion of the
between- period events and no appreciable effect on re-
sults was noted, thus these events were excluded, resulting
in 280 AEs for final analysis. Figure 2 depicts the reasons
for exclusion of subjects and AEs from final analysis.
None of the subjects experienced any grade 3 or 4
AEs, thus the main primary endpoint (percentage of
subjects experiencing at least one SAE) was 0 % for each
treatment arm. All subjects experienced at least one
grade 1 AE during each treatment period. The probabil-
ity of detecting any adverse event during the active
period but not during placebo period, and vice versa,
was thus 0. Among all grades, 159 (56.8 %) AEs oc-
curred during the active period and 121 (43.2 %) during
the placebo period. There were 254 (90.7 %) grade 1 and
26 (9.3 %) grade 2 AEs. Of the grade 1 AEs, 136 (53.5 %)
occurred following DAS181 and 118 (46.5 %) occurred
following placebo administration. The majority (23; 88.5 %)
of grade 2 AEs were observed during the active drug
period. Four (40 %) of the subjects experienced a grade 2
AE in the active drug but not the placebo period, whereas
only 1 (10 %) of the subjects had a grade 2 AE in the pla-
cebo but not the active drug period. However, this associ-
ation between exposure to DAS181 and grade 2AE was
not statistically significant (exact test p = 0.375).
With regard to assigned relatedness of study drug ad-
ministration to AE, there were 5 (1.8 %) AEs classified





Median (IQR) 22.5 (22, 40)
Sex
Female 7 (70 %)
Male 3 (30 %)
Race
White 5 (50 %)
Black or African American 3 (30 %)
Asian 1 (10 %)
Multi-Racial 1 (10 %)
Body Mass Index (kg/m2)
Median (IQR) 23.0 (21.4, 24.3)
FEV1, Baseline (day 0)
Median (IQR) 3.09 (2.78, 3.62)
FEV1 % Predicted, Baseline (day 0)
Mean (SD) 95.1 (11.6)
PC20, Baseline (screening, mg/m
2)
Median (IQR) 1.79 (0.49, 3.62)
Asthma Medications (baseline)
Short Acting Beta Agonist, inhaled 9 (90 %)
Long Acting Beta Agonist/Glucocorticoid, inhaled 2 (20 %)
Glucocorticoid, inhaled 1 (10 %)
Leukotriene-receptor antagonist 2 (20 %)
Abbreviations: IQR interquartile range, FEV1 forced expiratory volume in
1 second, SD standard deviation, PC20 provocative concentration producing a
20 % decline (PC20)
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as definitely related, 23 (8.2 %) probably related, 100
(35.7 %) possibly related, 109 (38.9 %) unlikely related,
and 43 (15.4 %) unrelated. Figure 3 graphically depicts
the AEs by relatedness to study drug and grade, accord-
ing to period. Of the 28 definitely or probably related
AEs, all occurred during the active drug period of study;
this represented a statistically significant association
between exposure to DAS181 and experiencing a defin-
itely or probably related AE (8 discordant pairs, exact
test p = 0.0039).
Overall, AEs most commonly occurred on study days 2
(50/280, 17.9 %), 1 (47/280, 16.8 %), and 3 (43/280,
15.4 %). When examined by period, AEs were most likely
to occur on days 2 (21/121, 17.4 %), 3 (20/121, 16.5 %),
22 Subjects 
Screened 
11 Subjects Enrolled 
318 Total AEs  
11 Subjects Did Not Meet 
 Inclusion/Exclusion Criteria 
11 Subjects Completed  
Initial Phase  
1 Subject Withdrew After 
Initial Phase 
10 Evaluable Subjects 
Completed Both Phases 
280 AEs for Analysis
27 AEs Occurred Before 
Initial Study Drug Dosing  
2 AEs in Subject 
Who Withdrew  
9 AEs Occurred  
Between Phases  
Fig. 2 Flow chart depicting reasons for exclusion of subjects and adverse events from final analysis. Half of the 22 screened subjects failed to
meet inclusion or exclusion criteria. One enrolled subject withdrew after the initial period thus his data was excluded from the final analysis
according to protocol. Adverse events that occurred before dosing or between periods were also excluded. Ultimately, ten subjects accounted








































AE Relatedness to Study Drug by Grade
DAS181 Placebo
Fig. 3 Distribution of adverse events by grade and relatedness, according to study period. Of the 280 total AEs, 56.8 % occurred during the active
period and 43.2 % during the placebo period. 254 (90.7 %) AEs were grade 1 and 26 (9.3 %) grade 2. While only 28 (10 %) AEs were classified as
definitely or probably related, all 28 occurred during the active period, representing a statistically significant association between exposure to
DAS181 and experiencing a definitely or probably related AE (8 discordant pairs, exact test p = 0.0039)
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and 10 (20/121, 16.5 %) during the placebo period, and
days 1 (30/159, 18.9 %), 2 (29/159, 18.2 %), and 3 (23/159,
14.5 %) during the active drug period.
The most common AE overall was chest discomfort
related to respiration (35/280, 12.5 %), followed by
microscopic hematuria (27/280, 9.6 %), wheezing (25/
280, 8.9 %), cough of any type (20/280, 7.1 %) and dys-
pnea (19/280, 6.8 %). The majority of instances of AE
due to microscopic hematuria were attributable to a dis-
crepancy between the normal range for urine red blood
cells used by the NIH Department of Laboratory Medi-
cine and the DAIDS standard scale which was employed
per protocol for AE grading, rather than a true clinical
abnormality. Figure 4 shows the distribution of the most
common AEs by period and grade, excluding micro-
scopic hematuria as it was deemed unlikely to be rele-
vant. When assessed by assigned relationship, dyspnea
(3/5, 60 %), dry cough (1/5, 20 %), and chest discomfort
related to respirations (1/5, 20 %) were the types of AEs
classified as definitely related; all definitely related AEs
occurred in a single subject. The four most common
AEs classified as probably related were chest discomfort
related to respirations (4/23, 17.4 %) elevated alkaline
phosphatase (4/23, 17.4 %), elevated aspartate amino-
transferase (3/23, 13 %), and prolonged aPTT (3/23,
13 %). One subject had a decrease in FEV1 to <80 %
predicted during the active drug period that was des-
ignated as probably related.
Specific safety laboratory findings of note
Alkaline phosphatase
There were seven grade 1 and one grade 2 elevations in
alkaline phosphatase levels among six subjects during
the course of the study. All occurred during the active
drug period, with peak values recorded at day 3 or day
10. All alkaline phosphatase values had returned to base-
line prior to crossover in those subjects who had eleva-
tions in the initial period, Interestingly, the grade 2
elevation was detected on day 3 in the same subject in
whom the third dose of study drug was withheld due to
concerns about adverse respiratory effects.
PTT/KCT
Six subjects had minor elevations in aPTT; however,
only three had abnormalities that reached grade 1 on the
DAIDS severity scale. All grade 1 elevations of aPTT
were transient and occurred on day 2 or 3 of the active
drug period; all resolved by the day 10 follow up visit.
All corresponding KCTs were within normal limits.
Microbiology
There were a total of four positive sputum cultures from
study subjects while on study. The identified organisms
included Moraxella (Branhamella) catarrhalis, Beta-
hemolytic Group F Streptococcus, Haemophilus influen-
zae, and methicillin susceptible Staphylococcus aureus.
All accompanying gram stains revealed squamous epi-
thelial cells and mixed oropharyngeal flora suggesting
oropharyngeal contamination. None of the organisms
were felt to be associated with true infection and thus
were not treated with antibiotics. Only the Group F
Streptococcus was isolated during the DAS181 treatment
period; the other three were isolated during the placebo
period. One additional subject had Neisseria meningiti-
dis isolated from sputum 2 months after completing the
study; of note, that subject had received DAS181 during
the initial period and had multiple sputum samples with
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Grade 1 Gedar 2
Number of AEs






Fig. 4 Distribution of most common adverse event types by study period and grade. The respiratory symptoms depicted in this figure accounted
for 99 adverse events and represented four of the most common adverse events overall. The variable depicted as “Cough (all types)” included all
cough related AEs including dry cough, cough not otherwise specified, and productive cough. The majority of AEs were grade 1, however all
grade 2 AEs in this group occurred during the active period
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Secondary outcomes
Change in post-dose FEV1
There was a 50 milliliter (mL) [IQR −110 mL, 40 mL]
overall decrease in median FEV1 following administra-
tion of DAS181, and a 35 mL [−40 mL, 140 mL]
increase after placebo dosing, representing a −1.9 % and
1.1 % change, respectively. This overall difference was
not statistically significant (p = 0.45), nor were any of the
differences by dosing day. Of note, one subject did
experience a clinically significant decrease in FEV1 after
receiving their 3rd dose of DAS181 (430 mL decrease;
11.7 %); the same subject also had a 340 mL decrease
(10.1 %) with their first dose of placebo (crossover
period) and a 20.8 % increase with the 3rd dose of pla-
cebo. Figure 5 shows the median % change in FEV1 after
dosing with either DAS181 or placebo, examined by day.
Day 3 change in FEV1 from baseline
The mean change from baseline FEV1 % to 24 h after
the 3rd dose (Day 3) was −1.7 % (median −2, IQR 11)
decrease for DAS181 and - 2.7 % (median 1, IQR 16)
decrease for placebo. There was not a statistical differ-
ence by treatment period.
Acute change in oxyhemoglobin saturation
No subject experienced a significant decline in oxyhemo-
globin saturation (SpO2), specified a priori as ≥4 % decline
in SpO2, following inhalation of either DAS181 or pla-
cebo. The mean acute change (post dose minus pre dose)
in SpO2 was 0.2 % ± 1.4 % following DAS181 administra-
tion and 0.5 % ± 1.4 % following placebo. The maximum
decrease in SpO2 1 h post dose for each period was 3 %
with active study drug and 2 % with placebo.
Acute asthma exacerbations of underlying lung disease
Two subjects (20 %) experienced grade 2 events charac-
terized as asthma exacerbations during the study period.
Both exacerbations occurred on day 0 of the active
period following administration of the initial dose of
DAS181. The final dose of DAS181 was withheld at the
investigators’ discretion from one of the subjects who
experienced an asthma exacerbation during the study
period. None of the subjects had documented asthma
exacerbations during the placebo period however one
additional subject did experience an asthma exacerba-
tion after completing screening but before receiving a
dose of either DAS181 or placebo.
Daily peak expiratory flow readings
The morning peak flow was similar in each study period,
with an overall median of 449 L/min [IQR 342, 532] in
the DAS181 period and 429 liters per minute (L/min)
[IQR 339, 546] in the placebo period. However, half the
subjects had missing peak flow readings thus limiting
the validity of this measurement and further analysis.
Airway hyper-responsiveness
There was no appreciable adverse effect on airway
hyper-responsiveness with DAS181 24-hours after dos-
ing completed (p = 0.1093).
6-minute walk distance and oxygen saturation
There was a small increase in median distance walked
on day 3 compared to baseline in both periods (DAS181:
19 m [IQR −9, 43]; placebo: 11.5 m [−14, 42]). None of
the subjects experienced a clinically significant decline
in SpO2 on either period. The median change in Sp02
with exertion was 0 % [IQR 0, 1] in the active period
and a decline of 1 % [IQR −1, 1] in the placebo period.
Rescue medication usage during active drug or placebo
study period
Use of rescue medication was documented a total of 77
times during the study, 58 times in active drug period
[median 0, range 0 to 9] and 19 times in placebo period
[median 0, range 0 to 2]. During the active period, the
highest uses of rescue medication occurred on dosing
Days 0 (10), 1 (10), and 2 (12). There was not a clearly
discernible pattern during the placebo period. Although
there was a significant difference in the total number of
times rescue medication use was recorded on active ver-
sus placebo period (paired t-test, p value 0.008), there
was not a significant association between exposure to
DAS181 and the need for any rescue medication use










DAS 181 Placebo DAS 181 Placebo DAS 181 Placebo


















Study Phase by Dosing Day
Fig. 5 Percent (%) change in post-dose FEV1 compared to pre-dose,
by dosing day. The change in median FEV1 following DAS181 versus
placebo dosing was not statistically different either overall (p = 0.45)
or by dosing day
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one subject accounting for much of the difference in
total medication usage, recording rescue medication use
20 times in the active period and 2 in the placebo.
Health related quality of life
Health related quality of life was assessed via multiple
modalities. There were not any detectable differences by
period on SF-36, nor did any of the mean change values
reach a level considered to be a minimally important dif-
ference (MID). Similarly, neither a statistically significant
nor a MID from baseline was detected between periods
with the ACS. There was a statistically significant differ-
ence in the overall mean change in AQLQ from baseline
(p = 0.0055), however the mean difference (−0.175) did
not reach the MID standard for AQLQ (0.5).
Discussion
Influenza virus infection is a major cause of morbidity
and mortality worldwide. There are limited treatment
options for IFV currently available, and emerging viral
resistance threatens existing agents. Individuals with
underlying lung disease have historically been among
the highest risk for IFV related complications; however,
they may also be more prone to treatment related
adverse effects, most notably respiratory problems, par-
ticularly when the agent is administered by inhalation.
Prior phase I and II studies of DAS181, an inhaled
antiviral with a unique mechanism of action that may be
associated with a higher barrier to antiviral resistance
development, have been promising in human subjects
who have been generally healthy at baseline. Among
subjects without known underlying disease, there have
not been any significant alteration in lung function de-
tected, nor has there been a significant difference in the
rate of serious adverse events with DAS181 treatment
versus placebo [6]. DAS181 has also showed promising
antiviral activity, suggesting that further development of
this novel antiviral drug is warranted. Assessing the
safety of this inhalational agent in individuals who have
underlying comorbidities, particularly lung disease, is ne-
cessary to help guide such development.
In this small, phase I study, DAS 181 was not associ-
ated with any serious adverse events (grade 3 or higher)
in well-controlled subjects with asthma. There were
more total AEs in the DAS181 period than the placebo
(56.8 % vs. 43.2 %), and 88.5 % of the grade 2 AEs oc-
curred during the active period. However, a statistically
significant association between exposure to DAS181 and
experiencing any AE, a grade 1 AE, or a grade 2 AE was
not detected.
With regard to the respiratory effects of DAS181 in
subjects with asthma, there were mixed findings. On the
one hand, there were no clinically significant changes in
oxyhemoglobin saturation or detectable worsening of
airway hyper-responsiveness with DAS181 administra-
tion. There also was not a significant overall change in
airflow, measured by post-dose FEV1, in the active vs
placebo period. On the other hand, one subject did
experience a significant (>10 %) acute decline in FEV 1
after DAS181 administration, but also experienced a
similar decline after inhalation of placebo. Another sub-
ject’s percent predicted FEV1 dropped below 80 %
acutely following DAS181 dosing. There was also a sta-
tistically significant association between exposure to
DAS181 and experiencing a definite or probably related
AE of any grade, with respiratory complaints being the
most common of these AEs. Two subjects experienced
events characterized as an asthma attack after the initial
dose of DAS181 was administered; the final dose of
DAS181 was not administered to one of these subjects
due to respiratory concerns. Both subjects who experi-
enced asthma exacerbations were successfully managed
with an inhaled corticosteroid.
This study was undertaken to investigate the safety
and tolerability of DAS181 in subjects with well con-
trolled asthma. The crossover design allowed subjects to
serve as their own controls, thus decreasing one of the
most prevalent confounding factors in asthma research,
inter-subject variability. The relatively complex study de-
sign required by the crossover comparisons also permit-
ted each participant to undergo more frequent clinical
assessments than usual, increasing our ability to assess
safety and monitor for transient AEs. The relatively
small size of the study did influence the power to detect
significant differences between groups, thus affecting
the strength of formal comparisons. However, for safety
reasons, this small number was by design. The goal of
ten evaluable subjects with asthma completing both
periods was reached, permitting preliminary assessment
of safety and tolerability while minimizing the potential
risk to human subjects being exposed to an investiga-
tional agent.
Conclusions
In summary, DAS181 was generally well tolerated in this
small study of otherwise healthy subjects with mild,
well-controlled asthma. However, the small sample size
and generally well-controlled nature of the subjects’
asthma at baseline limits generalizability of the result to
all asthmatics, particularly those at the severe end of
disease activity. Although there were no serious adverse
effects detected that would preclude further investiga-
tion of this agent in people with underlying asthma, the
possibility that individuals who have more reactive
airway disease at baseline may experience more adverse
effects following inhalation of the study drug remains.
The increased association of respiratory events classified
as being probably or definitely associated with DAS181
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in this study, including asthma exacerbations in two sub-
jects, suggests that caution may need to be employed
when administering DAS181 to individuals with less
stable reactive airway disease. Further investigation in a
controlled setting of the safety and efficacy of DAS181
in a larger population of asthmatic subjects at different
levels of disease activity is clearly warranted.
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